Sign In
12 Jul 2010 09:00
|
Press Release |
12 July 2010 |
LiDCO Group Plc
("LiDCO" or the "Company")
Director's Share Transaction
The Board of LiDCO Group Plc (AIM:LID), the cardiovascular monitoring company, was informed on 9 July 2010 that Mr John Barry, Sales and Marketing Director, transferred 422,500 ordinary shares in the Company into the name of his wife, Mrs Jane Barry, also on 9 July 2010.
Mr Barry's beneficial interest in the Company's ordinary shares remains unchanged at 429,642 shares, representing 0.25% of the Company's issued ordinary share capital.
- ENDS -
For more information please contact:
|
LiDCO Group Plc |
|
|
Terry O'Brien - Chief Executive John Rowland - Company Secretary |
Tel: +44 (0)20 7749 1500 www.lidco.com |
|
FinnCap |
|
|
Geoff Nash / Stephen Norcross / Henrik Persson |
+44 (0)20 7600 1658 www.finncap.com |
Media enquiries
|
Abchurch Communications |
|
|
Heather Salmond / Joanne Shears / Simone Elviss |
+44 (0)20 7398 7728 www.abchurch-group.com |
|
simone.elviss@abchurch-group.com |
|
About LiDCO Group Plc
LiDCO is a supplier of minimally invasive hemodynamic equipment to hospitals, to monitor the amount of blood flowing around the body and ensure that vital organs are adequately oxygenated. LiDCO's products facilitate the measurement, analysis, audit, training and sharing of real-time and historic hemodynamic data, in both critical care units and the operating theatre.
Scientific evidence is increasingly linking the optimisation of patients' hemodynamic status with better outcomes and reduced hospital stays and LiDCO's computer-based technology, developed at St Thomas' Hospital in London, has been shown to significantly reduce morbidity and complications, length of stay & overall costs associated with major surgery.
Key Products:
|
LiDCOplus: a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%) |
|
|
LiDCOrapid: a cardiac output monitor designed specifically for use in the operating theatre for fluid and drug management. The monitor enables anesthetists to get accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being before, during and after surgery. The LiDCOrapid provides: |
|
|
·; |
early and rapid warning of hemodynamic change to aid choice of therapeutic route: fluid or drug |
|
·; |
quantification of hemodynamic response, |
|
·; |
guidance on effective delivery of fluids to ensure the right amount at the right time |
|
LiDCOview: an easy-to-use graphical display of historical LiDCOplus and LiDCOrapid hemodynamic data. |
|
All LiDCO monitors use single-patient disposables (sensors or smartcards) which provide an ongoing revenue stream. LiDCO, in collaboration with Covidien (Nasdaq: IDYN), is currently developing a simultaneous brain and hemodynamic monitoring platform to provide clinicians with the market's most evolved fluid and hemodynamic monitoring product for high-risk surgery patients.
Clinical Validation & Education
LiDCO has been selected as the sole technology for two ongoing multi-centre government-funded studies in the UK and US. OPTIMISE is sponsored by the UK Government for optimising cardiovascular management in high-risk abdominal surgery patients and in the US, MOnIToR is a US Government sponsored transplantation donor organ optimisation study. The Company has also developed a hemodynamic workshop at St George's Hospital, London.
LiDCO Distribution Network:
LiDCO products are sold through Covidien's sales force in the US. LiDCO's strategy is to sell directly to hospitals in the UK, and through a network of specialty critical care and anesthesia distributors in the rest of the world.
LiDCO's sales office is in Cambridge, its manufacturing facility and headquarters are in London and its shares are traded on AIM. For more information please see www.lidco.com.
Follow the stocks
